SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
RPRX

Royalty Pharma plc (NASDAQ:RPRX)

US · Delayed Price · Currency is USD
Healthcare · Medical - Pharmaceuticals
$68.45+$0.73 (+1.08%)
 
Market cap
$30.5B
Insider Score
Health Score
Analyst consensus
Listed since
Jun 16, 2020
Market Cap$30.48B+75.9%
Revenue (ttm)$2.62B+11.4%
Net Income$671.45M-12.2%
EPS$1.53-13.1%
Shares Out445.27M
PE Ratio40.98
Forward PE11.62
Dividend$0.94(1.37%)
Ex-Dividend DateNov 13, 2026
Volume3,531,035
Open$68.17
Previous Close$67.72
Day's Range$67.95 - $68.83
52-Week Range$37.31 - $70.37
Beta0.41
AnalystsBuy
Price Target$71.00(+3.73%)
Earnings DateFeb 10, 2027

About RPRX

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Address
110 East 59th Street, New York, NY, 10022, US
Market Cap
30.48 billion
Employees
100
Industrial Classification
Medical - Pharmaceuticals

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$39.22M
Bought
$0

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
3 Buy0 Hold0 SellAvg target $66.67 (-2.6%)

3 firms rating RPRX in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Sound
From RPRX’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
+1.08%
5 Days
-2.21%
1 Month
+10.14%
6 Months
+27.82%
1 Year
+75.87%

$RPRX stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in RPRX holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by RPRX's directors and management

Net Shares Purchased by Insiders−400k−200k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

RPRX Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New RPRX patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to RPRX from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in RPRX

VXFVanguard Extended Market ETF$339.19M
VFLOVictoryShares Free Cash Flow ETF$246.09M
IWRiShares Russell Mid-Cap ETF$120.18M
VYMVanguard High Dividend Yield ETF$113.10M
IHEiShares U.S. Pharmaceuticals ETF$81.87M
CGDGCapital Group Dividend Growers ETF$81.49M

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from RPRX’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
0
Analyst Ratings
32% of score
78
News & Sentiment
20% of score
62

News check: Analyst upgrades and earnings beat offset neutral conference appearances and comparison articles with mixed conclusions.

Recent Insider Activity

Buys
0
Sells
15
Buy Value
$0
Distinct Buyers
0

Insider Score Trend Over Time

-38.0 since Aug 21
0255075100Aug 21 — Insider Score 38.0Aug 22 — Insider Score 38.0Aug 23 — Insider Score 38.0Aug 24 — Insider Score 38.0Aug 25 — Insider Score 38.0Aug 26 — Insider Score 38.0Aug 27 — Insider Score 38.0Aug 28 — Insider Score 38.0Aug 29 — Insider Score 38.0Aug 30 — Insider Score 38.0Aug 31 — Insider Score 38.0Sep 1 — Insider Score 0.0Sep 2 — Insider Score 0.0Sep 3 — Insider Score 0.0Sep 4 — Insider Score 0.0Sep 5 — Insider Score 0.0Sep 6 — Insider Score 0.0Sep 7 — Insider Score 0.0Sep 8 — Insider Score 0.0Sep 9 — Insider Score 0.0Sep 10 — Insider Score 0.0Sep 11 — Insider Score 0.0Sep 12 — Insider Score 0.0Sep 13 — Insider Score 0.0Sep 14 — Insider Score 0.0Sep 15 — Insider Score 0.0Sep 16 — Insider Score 0.0Sep 17 — Insider Score 0.0Sep 18 — Insider Score 0.0Sep 19 — Insider Score 0.0Sep 20 — Insider Score 0.0Sep 21 — Insider Score 0.0Sep 22 — Insider Score 0.0Sep 23 — Insider Score 0.0Sep 24 — Insider Score 0.0Sep 25 — Insider Score 0.0Sep 26 — Insider Score 0.0Sep 27 — Insider Score 0.0Sep 28 — Insider Score 0.0Sep 29 — Insider Score 0.0Sep 30 — Insider Score 0.0Oct 1 — Insider Score 0.0Oct 2 — Insider Score 26.0Oct 3 — Insider Score 0.0Oct 4 — Insider Score 0.0Aug 21Sep 12Oct 4

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

PBEInvesco Biotechnology & Genome ETF5.55%
ELCFEventide Large Cap Focus ETF5.41%
PTNTCorgi ETF Trust I - Corgi IP Licensing & Royalties ETF4.90%
IHEiShares U.S. Pharmaceuticals ETF4.78%
ELCVEventide High Dividend ETF4.51%
ETDGEventide Dividend Growth ETF4.51%
BTALAGF U.S. Market Neutral Anti-Beta Fund4.27%
ADPVAdaptiv Select ETF4.10%
TFGZThornburg Focus Growth Fund3.50%
GFLWVictory Portfolios II - Victoryshares Free Cash Flow Growth ETF3.15%
SAMMStrategas Macro Momentum ETF2.95%
MVFDMonarch Volume Factor Dividend Tree ETF2.76%

Weight is the stock’s share of each fund’s holdings.